Skip to content

Precision application of tolvaptan in volume management of patients with renal disease

Precision application of tolvaptan in volume management of patients with renal disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075274
Enrollment
Unknown
Registered
2023-08-31
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute and chronic kidney disease (non-dialysis) with fluid retention

Interventions

Tolvaptan group:Tolvaptan
Tolvaptan + tab diuretics group:Tolvaptan + tab diuretics
tab diuretics group: tab diuretics

Sponsors

Affiliated Zhongda Hospital of Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1: Patients with acute or chronic renal disease with fluid retention (telescopic breathing, edema, jugular venous congestion, pulmonary rales, signs of pulmonary congestion on chest radiograph or chest CT) who require or are on diuretic therapy 2: 18 years old = age = 85 years old

Exclusion criteria

Exclusion criteria: 1: Undergoing renal replacement therapy 2: People with cognitive impairment, consciousness impairment, etc. who are unable to communicate normally

Design outcomes

Primary

MeasureTime frame
Weight;

Secondary

MeasureTime frame
daily urine output;Alb, Prealb;Cr, BUN, Serum glucose;K, P, Ca; urine osmolality;urine specific gravity;Edema grading;Body water content;Length of stay;Hb;cost of hospitalization; pulmonary rales; jugular venous congestion;dyspnea score;

Countries

China

Contacts

Public ContactWang Bin

Affiliated Zhongda Hospital of Southeast University

wangbinhewei@126.com+86 133 7225 3855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026